CADL
Candel Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.85
−4.32%Sep 10, 2026, 12:22 UTC
Candel Therapeutics, Inc. appointed Martine Zimmermann as a director, effective September 8, 2026.
Aug 13, 2026, 12:05 UTC
Candel Therapeutics announced its financial results for the second quarter ended June 30, 2026.
Source:Jun 30, 2026, 12:05 UTC
Candel Therapeutics initiated a global pivotal Phase 3 AURORA trial evaluating aglatimagene besadenovec (CAN-2409) in advanced non-small cell lung cancer patients with inadequate response to immune checkpoint inhibitors.
Source:Jun 1, 2026, 20:05 UTC
Candel Therapeutics granted stock options to three new employees on May 31, 2026.